Log in or register to see all Alerts
New HTA Decisions in Scotland
March 2021
Drug name
ERLEADA® (apalutamide)
Company
Janssen-Cilag Ltd
Decision date
04/12/2020
Therapeutic area
Cancer
Therapeutic sub area
Prostate cancer
Decision
Not recommended
Indication
In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, apalutamide (ERLEADA®) is not recommended for use within NHS Scotland.
Summary
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result the SMC cannot recommend its use within NHS Scotland.